Scarica l'app Stockscreener
52.15
0.38%
0.20
Dopo l'orario di chiusura:
52.29
0.14
+0.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$51.95
Aprire:
$51.99
Volume 24 ore:
15.66M
Relative Volume:
0.98
Capitalizzazione di mercato:
$106.16B
Reddito:
$48.03B
Utile/perdita netta:
$6.05B
Rapporto P/E:
17.61
EPS:
2.9615
Flusso di cassa netto:
$15.30B
1 W Prestazione:
+6.00%
1M Prestazione:
+12.22%
6M Prestazione:
+9.01%
1 anno Prestazione:
-11.37%
Intervallo 1D:
$51.69
$52.51
Intervallo di 1 settimana:
$48.22
$52.51
Portata 52W:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Confronta BMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
52.15 | 105.76B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,010.31 | 907.99B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.93 | 487.83B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
226.08 | 404.22B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.16 | 254.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.72 | 250.41B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Iniziato | Piper Sandler | Overweight |
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Cresset Asset Management LLC Decreases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Epoch Investment Partners Inc. - MarketBeat
Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable” - Insider Monkey
Do These 3 Healthcare Stocks Need a Checkup? - The Motley Fool
What's Going On With Bristol-Myers Squibb Stock Friday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol Myers Squibb CEO Chris Boerner says company culture was the missing piece of his ‘patent cliff’ plan - Fortune
First Trust Advisors LP Has $212.59 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) – Company AnnouncementFT.com - Financial Times
DEERFIELD MANAGEMENT COMPANY, L.P.'s Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Rx Rundown: Bristol Myers Squibb, Retro Bio, Ionis Pharmaceuticals and more - Medical Marketing and Media
How risky is Bristol Myers Squibb Company stock compared to peers2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - Newser
Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities - Sahm
BMY Gains on News of Continuation of Alzheimer's Disease Study - Finviz
Florida key to BMS slip in ADP? Acadia sails ahead - BioWorld MedTech
Scotiabank raises Bristol-Myers Squibb stock price target to $53 on pipeline - Investing.com Nigeria
Invesco Ltd. Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
CW Advisors LLC Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Why Bristol Myers Squibb Company Celegne Contingent stock is a must watch tickerGlobal Markets & Stock Timing and Entry Methods - Newser
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025 - ts2.tech
What's Going On With Bristol-Myers Squibb Shares Wednesday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol-Myers Squibb stock holds Buy rating at Truist despite trial delay - Investing.com
A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why. - MarketWatch
After finding ‘irregularities,’ Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis - BioPharma Dive
Bristol Myers Squibb (BMY) Delays Alzheimer's Drug Trial Results - GuruFocus
Bristol Myers (BMY) Extends ADEPT-2 Study Timeline for Key Alzhe - GuruFocus
Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial C - GuruFocus
Bristol Myers (BMY) Bolsters ADEPT-2 Alzheimer's Study with More Participants - GuruFocus
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb - Yahoo Finance
Bristol Myers Stock Jumps As Wall Street Backs Added Enrollment In Alzheimer’s Trial — Retail Calls It ‘Worth A Play’ - Stocktwits
Drug Trial Wins Give Health Care Stocks A Shot - Finimize
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Bristol Myers rises as Alzheimer's trial to enroll more patients - TradingView
M&T Bank Corp Sells 23,588 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers (BMY) Expands ADEPT-2 Study to Address Irregularit - GuruFocus
River Road Asset Management LLC Sells 67,650 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
BMS to enroll more patients in Alzheimer’s psychosis drug trial - Investing.com
Bristol Myers Squibb stock rises after continuing Phase 3 Alzheimer’s study - Investing.com Canada
Loomis Sayles & Co. L P Boosts Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Independent Franchise Partners LLP Increases Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Stock Rises on Alzheimer’s Drug Study Update - The Wall Street Journal
Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates - Insider Monkey
BMS Executive: AI to Reshape Pharmaceutical, Biotech Industries - 조선일보
Bristol-Myers Squibb (BMY): Assessing Value After a Recent Short-Term Share Price Rebound - simplywall.st
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Judge Trims but Revives Core Claims in Bristol-Myers $6.7B Suit - USA Herald
BMY: Goldman Sachs Raises Bristol-Myers Squibb Price Target to $57 | BMY Stock News - GuruFocus
Bristol-Myers to Face $6.7 Billion Celgene Deal Payout Suit (1) - Bloomberg Law News
Wealthedge Investment Advisors LLC Buys New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Shelton Capital Management Cuts Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Claret Asset Management Corp Grows Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Faces $6.7 Billion Lawsuit Over Celge - GuruFocus
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
0.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):